Breast Cancer Clinical Trials

Showing 2261-2280 of 5,597 trials

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00036868

RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, methotrexate, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with trastuzumab may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining combination chemotherapy with trastuzumab in treating women who have metastatic breast cancer.

Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC90 participantsStarted Feb 2002

Antwerp, Belgium • Brussels, Belgium • Edegem, Belgium +10 more locations

TERMINATEDPhase 2

HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

NCT03322215

This is a randomized, 2-arm, open-label, multicenter, international phase II trial. A total of 196 patients will be included. The study will include patients with metastatic Hormone Receptor positive / Human Epidermal Growth Factor Receptor (HER2) negative breast cancer with progressive disease after endocrine treatment. Patients will be randomized (1:1) between two treatment arms: A. palbociclib + fulvestrant and b. capecitabine.

Breast Cancer Metastatic

Theodoros Foukakis42 participantsStarted Oct 2017

Gothenburg, Sweden • Malmo, Sweden • Stockholm, Sweden +6 more locations

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

Related Searches

Effects of Diet and Osteopathy on Quality of Life and Inflammation in Breast Cancer Patients Under Hormonal Therapy

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System

Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors

Comparing 5 and 15 Fractions for Whole Breast Irradiation After Breast Conserving Surgery

Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer Survivors

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients

Exercise Program in Cancer and Cognition

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients